B Mark Evers
Overview
Explore the profile of B Mark Evers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
9584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clarke H, Hawkinson T, Shedlock C, Medina T, Ribas R, Wu L, et al.
Nat Metab
. 2025 Mar;
PMID: 40069440
Lung adenocarcinoma (LUAD) is an aggressive cancer defined by oncogenic drivers and metabolic reprogramming. Here we leverage next-generation spatial screens to identify glycogen as a critical and previously underexplored oncogenic...
2.
Zhu B, Pitts M, Buoncristiani M, Bryant L, Lopez-Nunez O, Gurria J, et al.
Oncogene
. 2025 Feb;
PMID: 39956863
MYCN-amplification is a genetic hallmark of ~40% of high-risk neuroblastomas (NBs). Altered glycosylation is a common feature of adult cancer progression, but little is known about how genetic signatures such...
3.
Burus T, Hull P, Lang Kuhs K, Gao T, Brainson C, Evers B
J Am Coll Surg
. 2025 Feb;
PMID: 39912550
Background: The Appalachian region of the United States (US) extends from the Mississippi delta to southern New York. Although disparities in Appalachian cancer outcomes have long been observed, recent rates...
4.
McDonald H, Reagan A, Mosa Faisal A, Goettl R, Wang C, Hoyd R, et al.
J Am Coll Surg
. 2025 Jan;
PMID: 39868697
Background: Colon cancer is a leading cause of mortality in Appalachian Kentucky. Studies suggest that the microbiome may influence cancer outcomes. We investigate differential gene expression, the tumor microbiome, and...
5.
Kelson C, Tessmann J, Geisen M, He D, Wang C, Gao T, et al.
Cells
. 2024 Oct;
13(19).
PMID: 39404424
Dysregulated fatty acid metabolism is an attractive therapeutic target for colorectal cancer (CRC). We previously reported that fatty acid synthase (FASN), a key enzyme of de novo synthesis, promotes the...
6.
Li C, Zhou Y, Jiang Y, Yin Z, Weiss H, Wang Q, et al.
Cell Prolif
. 2024 Sep;
58(2):e13757.
PMID: 39329245
Intestinal stem cells differentiate into absorptive enterocytes, characterised by increased brush border enzymes such as intestinal alkaline phosphatase (IAP), making up the majority (95%) of the terminally differentiated cells in...
7.
Orozco G, Cannon R, Mei X, Inabnet 3rd W, Evers B, Gedaly R, et al.
Surgery
. 2024 Sep;
176(6):1754-1760.
PMID: 39299857
Background: Orthotopic liver transplantation is the recommended treatment option for patients with early-stage hepatocellular carcinoma and concomitant cirrhosis. Waitlist candidacy can be affected by social determinants of health that vary...
8.
Gupta M, Davenport D, Orozco G, Bharadwaj R, Roses R, Evers B, et al.
Surg Oncol
. 2024 Aug;
56:102114.
PMID: 39163797
Introduction: Despite superior outcomes with liver transplantation, cirrhotic patients with HCC may turn to other forms of definitive treatment. To understand perioperative outcomes, we examined perioperative mortality and major morbidity...
9.
Chow Z, Johnson J, Chauhan A, Jeong J, Castle J, Izumi T, et al.
Cancer Lett
. 2024 May;
596:216993.
PMID: 38801884
Ribonucleotide Reductase (RNR) is a rate-limiting enzyme in the production of deoxyribonucleoside triphosphates (dNTPs), which are essential substrates for DNA repair after radiation damage. We explored the radiosensitization property of...
10.
Tessmann J, Deng P, Durham J, Li C, Banerjee M, Wang Q, et al.
Chemosphere
. 2024 May;
359:142332.
PMID: 38754493
Perfluorooctanesulfonic acid (PFOS) is a widely recognized environment pollutant known for its high bioaccumulation potential and a long elimination half-life. Several studies have shown that PFOS can alter multiple biological...